Published in J Acquir Immune Defic Syndr on August 01, 2010
Breastfeeding, Antiretroviral, and Nutrition Study | NCT00164736
Nevirapine Resistance Study: Nevirapine Resistance Among HIV-Infected Mothers | NCT00164762
Stopping the control arm in response to the DSMB: mother's choice of HIV prophylaxis during breastfeeding in the BAN Study. Contemp Clin Trials (2011) 0.96
World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries. Clin Infect Dis (2012) 0.93
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission. PLoS One (2012) 0.90
Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine. J Infect Dis (2012) 0.85
Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS One (2011) 0.84
Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis. AIDS (2015) 0.77
Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis. Expert Rev Anti Infect Ther (2015) 0.76
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission. J Acquir Immune Defic Syndr (2016) 0.75
Viral Suppression and HIV Drug Resistance at 6 Months Among Women in Malawi's Option B+ Program: Results From the PURE Malawi Study. J Acquir Immune Defic Syndr (2017) 0.75
A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol (2004) 42.68
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet (1999) 18.20
Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med (2007) 6.65
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med (2004) 6.29
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS (2001) 5.31
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis (2005) 3.91
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis (2005) 2.54
Prevention of mother-to-child transmission: program changes and the effect on uptake of the HIVNET 012 regimen in Malawi. AIDS (2008) 2.48
Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials (2008) 2.35
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS (2007) 2.19
Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One (2007) 2.09
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis (2006) 2.08
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis (2009) 1.93
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med (2009) 1.90
A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. J Acquir Immune Defic Syndr (2008) 1.81
Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis (2007) 1.73
Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.67
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis (2010) 1.64
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS (2005) 1.58
Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit (2006) 1.53
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses (2007) 1.31
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis (2005) 1.20
Development of a highly efficient extraction technique and specific multiplex assay for measuring antiretroviral drug concentrations in breast milk. Ther Drug Monit (2007) 0.85
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care (2005) 9.89
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med (2010) 8.51
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
A meta-analysis of the association between adherence to drug therapy and mortality. BMJ (2006) 7.79
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA (2010) 5.94
Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med (2010) 5.85
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med (2009) 5.35
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care (2005) 4.78
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
Pregnancy and infection. N Engl J Med (2014) 4.15
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med (2008) 4.12
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Inpatient hysterectomy surveillance in the United States, 2000-2004. Am J Obstet Gynecol (2007) 3.86
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS (2006) 3.70
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem (2003) 3.61
Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci (2003) 3.54
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care (2005) 3.46
Physical activity level and health-related quality of life in the general adult population: a systematic review. Prev Med (2007) 3.45
Fertility treatments and multiple births in the United States. N Engl J Med (2013) 3.45
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med (2003) 3.32
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS (2007) 3.22
Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis (2011) 3.16
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA (2002) 2.94
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 2.89
An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity. Matern Child Health J (2007) 2.89
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int (2002) 2.83
Rapid HIV-1 testing during labor: a multicenter study. JAMA (2004) 2.81
Pandemic influenza and pregnant women. Emerg Infect Dis (2008) 2.80
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol (2004) 2.74
Integrating family planning and prevention of mother-to-child HIV transmission in resource-limited settings. Lancet (2005) 2.73
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther (2007) 2.71
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet (2012) 2.69
Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol (2010) 2.69
Tubal factor infertility and perinatal risk after assisted reproductive technology. Obstet Gynecol (2013) 2.66
Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS (2010) 2.62
Nrf2, a multi-organ protector? FASEB J (2005) 2.61
Differential gene expression patterns revealed by oligonucleotide versus long cDNA arrays. Toxicol Sci (2002) 2.61
Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ (2004) 2.55
Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A (2009) 2.54
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis (2005) 2.54
A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med (2002) 2.49
The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal (2009) 2.49
A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med (2004) 2.48
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis (2010) 2.45
Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43
Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 2.38
Inadequate coordination of maternal and infant HIV services detrimentally affects early infant diagnosis outcomes in Lilongwe, Malawi. J Acquir Immune Defic Syndr (2011) 2.38
Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp Clin Trials (2008) 2.35
Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci (2008) 2.34
NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem (2003) 2.33
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care (2012) 2.32
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA (2004) 2.31
Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30
Microalbuminuria in HIV infection. AIDS (2007) 2.28
Interim Guidelines for Pregnant Women During a Zika Virus Outbreak - United States, 2016. MMWR Morb Mortal Wkly Rep (2016) 2.27
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis (2011) 2.26